www.marketwatch.com

www.marketwatch.com
Share

www.marketwatch.com

 •  February 15

Getty Images Biogen Inc.’s crucial Alzheimer’s disease drug aducanumab is still a year or two from releasing key clinical trial results, but the company’s latest news may leave some investors feeling more circumspect. Because the company saw “more variability on the primary endpoint than assumed,” Biogen BIIB, +1.11% decided to increase the sample...

www.marketwatch.com

 •  January 31

Getty Images Pharmaceutical stocks dropped in Wednesday trade after President Donald Trump brought up the high prices of U.S. drugs in his State of the Union address. The SPDR S&P Pharmaceutical ETF XPH, -1.81% declined 1.5%, the SPDR S&P Biotech XBI, -2.05% declined nearly 1% and the Health Care Select Sector SPDR ETF XLV, -1.43% declined 1.1% in...

www.marketwatch.com

 •  December 28, 2017

GW Pharmaceuticals plc GWPH, -1.06% said early Thursday that the Food and Drug Administration will review a new drug application for its cannabis-derived drug epidiolex for seizures associated with two rare types of childhood epilepsy. The application was accepted for priority review, a special status that offers an accelerated review for...

www.marketwatch.com

 •  November 30, 2017

Amazon.com Inc. AMZN, +1.33% has had early talks with generic drug makers like Mylan NV MYL, -0.90% and Novartis AG's NVS, +0.76% Sandoz about a potential entry into the pharmacy business, according to a Thursday report. CNBC reported Thursday that health care investment bank Leerink confirmed that a Sandoz executive recently spoke with Amazon...

www.marketwatch.com

 •  November 20, 2017

Acorda Therapeutics Inc. ACOR, +9.55% shares dropped 2.5% in premarket trade Monday after the company said it will discontinue its Parkinson's disease drug tozadenant. The company said last Wednesday that several patients had died during tozadenant clinical trials and others had experienced serious blood-related complications. Acorda decided to...

www.marketwatch.com

 •  October 21, 2017

Do you know someone who has participated in a clinical drug trial? Years ago, your answer would probably have been no, but that may have changed. In recent years, the number of clinical drug trials has increased dramatically and researchers are looking for participants. According to ClinicalTrials.gov, as of late August, more than a quarter million...

www.marketwatch.com

 •  October 18, 2017

PALM BEACH, Florida, Oct 18, 2017 (PR Newswire Europe via COMTEX) -- PALM BEACH, Florida, October 18, 2017 /PRNewswire/ -- The new-drug pipeline is bursting with innovative treatments in clinical trials while the industry is growing by leaps and bounds. Many biotech stocks are catching the attention of Wall Street as new milestones and major...

www.marketwatch.com

 •  October 13, 2017

After months of headlines about astronomical drug prices, a funny thing’s happening — drug costs are plummeting. One of the big surprises in the consumer price report for September released by the Labor Department was the big slowdown in medical-care costs. Also read: U.S. inflation surges again after hurricane boosts gas prices, CPI shows In the...

www.marketwatch.com

 •  October 11, 2017

Getty Images If successful, a new drug from the biotech Myovant Sciences Ltd. could treat two women’s health disorders, as well as prostate cancer. The drug, Relugolix, works to reduce estrogen in women and testosterone in men. The hormones are factors in two painful conditions affecting women, uterine fibroids and endometriosis, and in prostate...

www.marketwatch.com

 •  October 9, 2017

Sarepta Therapeutics Inc. SRPT, +1.08% shares surged nearly 3% in premarket trade Monday after RBC Capital Markets analyst Matthew Eckler said he sees a "compelling argument" for faster-than-normal approval of Sarepta's Duchenne muscular dystrophy drug golodirsen. Sarepta recently released positive early/mid-stage clinical trial results for the DMD...